» Articles » PMID: 33771105

Drug-drug Interactions in Subjects Enrolled in SWOG Trials of Oral Chemotherapy

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2021 Mar 27
PMID 33771105
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with cancer are at increased risk of drug-drug interactions (DDI), which can increase treatment toxicity or decrease efficacy. It is especially important to thoroughly screen DDI in oncology clinical trial subjects to ensure trial subject safety and data accuracy. This study determined the prevalence of potential DDI involving oral anti-cancer trial agents in subjects enrolled in two SWOG clinical trials.

Methods: Completed SWOG clinical trials of commercially available agents with possible DDI that had complete concomitant medication information available at enrollment were included. Screening for DDI was conducted through three methods: protocol-guided screening, Lexicomp® screening, and pharmacist determination of clinical relevance. Descriptive statistics were calculated.

Results: SWOG trials S0711 (dasatinib, n = 83) and S0528 (everolimus/lapatinib, n = 84) were included. Subjects received an average of 6.6 medications (standard deviation = 4.9, range 0-29) at enrollment. Based on the clinical trial protocols, at enrollment 18.6% (31/167) of subjects had a DDI and 12.0% (20/167) had a DDI that violated a protocol exclusion criterion. According to Lexicomp®, 28.7% of subjects (48/167) had a DDI classified as moderate or worse, whereas pharmacist review indicated that 7.2% of subjects (12/167) had a clinically relevant interaction. The majority of clinically relevant DDI identified were due to the coadministration of acid suppression therapies with dasatinib (83.3%, 10/12).

Conclusions: The high DDI prevalence in subjects enrolled on SWOG clinical trials, including a high prevalence that violate trial exclusion criteria, support the need for improved processes for DDI screening to ensure trial subject safety and trial data accuracy.

Citing Articles

Managing Drug Interactions With Oral Anticancer Treatments.

Lohr L, Blake K, Chan C, Sturm S, Walsh G J Adv Pract Oncol. 2023; 14(5):419-438.

PMID: 37576366 PMC: 10414528. DOI: 10.6004/jadpro.2023.14.5.7.


Precision antiplatelet therapy.

Rocca B, Patrono C Res Pract Thromb Haemost. 2023; 7(3):100138.

PMID: 37215094 PMC: 10193296. DOI: 10.1016/j.rpth.2023.100138.


Positive Patient Postoperative Outcomes with Pharmacotherapy: A Narrative Review including Perioperative-Specialty Pharmacist Interviews.

Parrish 2nd R, Bodenstab H, Carneal D, Cassity R, Dager W, Hyland S J Clin Med. 2022; 11(19).

PMID: 36233497 PMC: 9572852. DOI: 10.3390/jcm11195628.

References
1.
Marcath L, Xi J, Hoylman E, Kidwell K, Kraft S, Hertz D . Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics. J Oncol Pract. 2018; 14(6):e368-e374. PMC: 9797246. DOI: 10.1200/JOP.18.00086. View

2.
Mir O, Touati N, Lia M, Litiere S, Cesne A, Sleijfer S . Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. Clin Cancer Res. 2019; 25(5):1479-1485. DOI: 10.1158/1078-0432.CCR-18-2748. View

3.
Marcath L, Coe T, Hoylman E, Redman B, Hertz D . Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials. BMC Cancer. 2018; 18(1):1155. PMC: 6249716. DOI: 10.1186/s12885-018-5076-0. View

4.
Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus Felipe V . Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm. 2014; 36(6):1251-9. DOI: 10.1007/s11096-014-0029-4. View

5.
Eley T, Luo F, Agrawal S, Sanil A, Manning J, Li T . Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009; 49(6):700-9. DOI: 10.1177/0091270009333854. View